281 related articles for article (PubMed ID: 19738061)
1. BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells.
Mani M; Carrasco DE; Zhang Y; Takada K; Gatt ME; Dutta-Simmons J; Ikeda H; Diaz-Griffero F; Pena-Cruz V; Bertagnolli M; Myeroff LL; Markowitz SD; Anderson KC; Carrasco DR
Cancer Res; 2009 Oct; 69(19):7577-86. PubMed ID: 19738061
[TBL] [Abstract][Full Text] [Related]
2. Targeted disruption of the BCL9/β-catenin complex inhibits oncogenic Wnt signaling.
Takada K; Zhu D; Bird GH; Sukhdeo K; Zhao JJ; Mani M; Lemieux M; Carrasco DE; Ryan J; Horst D; Fulciniti M; Munshi NC; Xu W; Kung AL; Shivdasani RA; Walensky LD; Carrasco DR
Sci Transl Med; 2012 Aug; 4(148):148ra117. PubMed ID: 22914623
[TBL] [Abstract][Full Text] [Related]
3. miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/β-catenin/BCL9 pathway.
Zhao JJ; Lin J; Zhu D; Wang X; Brooks D; Chen M; Chu ZB; Takada K; Ciccarelli B; Admin S; Tao J; Tai YT; Treon S; Pinkus G; Kuo WP; Hideshima T; Bouxsein M; Munshi N; Anderson K; Carrasco R
Cancer Res; 2014 Mar; 74(6):1801-13. PubMed ID: 24599134
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia activates Wnt/β-catenin signaling by regulating the expression of BCL9 in human hepatocellular carcinoma.
Xu W; Zhou W; Cheng M; Wang J; Liu Z; He S; Luo X; Huang W; Chen T; Yan W; Xiao J
Sci Rep; 2017 Jan; 7():40446. PubMed ID: 28074862
[TBL] [Abstract][Full Text] [Related]
5. Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion.
Elsarraj HS; Hong Y; Valdez KE; Michaels W; Hook M; Smith WP; Chien J; Herschkowitz JI; Troester MA; Beck M; Inciardi M; Gatewood J; May L; Cusick T; McGinness M; Ricci L; Fan F; Tawfik O; Marks JR; Knapp JR; Yeh HW; Thomas P; Carrasco DR; Fields TA; Godwin AK; Behbod F
Breast Cancer Res; 2015 Sep; 17():128. PubMed ID: 26384318
[TBL] [Abstract][Full Text] [Related]
6. Loss of BCL9/9l suppresses Wnt driven tumourigenesis in models that recapitulate human cancer.
Gay DM; Ridgway RA; Müller M; Hodder MC; Hedley A; Clark W; Leach JD; Jackstadt R; Nixon C; Huels DJ; Campbell AD; Bird TG; Sansom OJ
Nat Commun; 2019 Feb; 10(1):723. PubMed ID: 30760720
[TBL] [Abstract][Full Text] [Related]
7. BCL9 Upregulation in Adrenocortical Carcinoma: A Novel Wnt/β-Catenin Activating Event Driving Adrenocortical Malignancy.
Brown TC; Nicolson NG; Korah R; Carling T
J Am Coll Surg; 2018 Jun; 226(6):988-995. PubMed ID: 29428231
[TBL] [Abstract][Full Text] [Related]
8. Serglycin proteoglycan is required for multiple myeloma cell adhesion, in vivo growth, and vascularization.
Purushothaman A; Toole BP
J Biol Chem; 2014 Feb; 289(9):5499-509. PubMed ID: 24403068
[TBL] [Abstract][Full Text] [Related]
9. BCL9 promotes epithelial mesenchymal transition and invasion in cisplatin resistant NSCLC cells via β-catenin pathway.
Zhang Y; Zhang Q; Chen H; Wang C
Life Sci; 2018 Sep; 208():284-294. PubMed ID: 30009824
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of developmentally regulated endothelial cell locus-1 inhibits the growth of colon cancer.
Zou X; Qiao H; Jiang X; Dong X; Jiang H; Sun X
J Biomed Sci; 2009; 16(1):33. PubMed ID: 19292890
[TBL] [Abstract][Full Text] [Related]
11. Fusion of the BCL9 HD2 domain to E1A increases the cytopathic effect of an oncolytic adenovirus that targets colon cancer cells.
Fuerer C; Homicsko K; Lukashev AN; Pittet AL; Iggo RD
BMC Cancer; 2006 Oct; 6():236. PubMed ID: 17020613
[TBL] [Abstract][Full Text] [Related]
12. The interactions of Bcl9/Bcl9L with β-catenin and Pygopus promote breast cancer growth, invasion, and metastasis.
Vafaizadeh V; Buechel D; Rubinstein N; Kalathur RKR; Bazzani L; Saxena M; Valenta T; Hausmann G; Cantù C; Basler K; Christofori G
Oncogene; 2021 Oct; 40(43):6195-6209. PubMed ID: 34545187
[TBL] [Abstract][Full Text] [Related]
13. Bcl9/Bcl9l are critical for Wnt-mediated regulation of stem cell traits in colon epithelium and adenocarcinomas.
Deka J; Wiedemann N; Anderle P; Murphy-Seiler F; Bultinck J; Eyckerman S; Stehle JC; André S; Vilain N; Zilian O; Robine S; Delorenzi M; Basler K; Aguet M
Cancer Res; 2010 Aug; 70(16):6619-28. PubMed ID: 20682801
[TBL] [Abstract][Full Text] [Related]
14. Wnt status-dependent oncogenic role of BCL9 and BCL9L in hepatocellular carcinoma.
Huge N; Sandbothe M; Schröder AK; Stalke A; Eilers M; Schäffer V; Schlegelberger B; Illig T; Vajen B; Skawran B
Hepatol Int; 2020 May; 14(3):373-384. PubMed ID: 31440992
[TBL] [Abstract][Full Text] [Related]
15. Wnt3a Promotes the Vasculogenic Mimicry Formation of Colon Cancer via Wnt/β-Catenin Signaling.
Qi L; Song W; Liu Z; Zhao X; Cao W; Sun B
Int J Mol Sci; 2015 Aug; 16(8):18564-79. PubMed ID: 26266404
[TBL] [Abstract][Full Text] [Related]
16. Wnt inhibitory factor 1 induces apoptosis and inhibits cervical cancer growth, invasion and angiogenesis in vivo.
Ramachandran I; Thavathiru E; Ramalingam S; Natarajan G; Mills WK; Benbrook DM; Zuna R; Lightfoot S; Reis A; Anant S; Queimado L
Oncogene; 2012 May; 31(22):2725-37. PubMed ID: 22002305
[TBL] [Abstract][Full Text] [Related]
17. Tumor Suppressive Role of ARHGAP17 in Colon Cancer Through Wnt/β-Catenin Signaling.
Pan S; Deng Y; Fu J; Zhang Y; Zhang Z; Ru X; Qin X
Cell Physiol Biochem; 2018; 46(5):2138-2148. PubMed ID: 29730655
[TBL] [Abstract][Full Text] [Related]
18. Alternative splicing of TIA-1 in human colon cancer regulates VEGF isoform expression, angiogenesis, tumour growth and bevacizumab resistance.
Hamdollah Zadeh MA; Amin EM; Hoareau-Aveilla C; Domingo E; Symonds KE; Ye X; Heesom KJ; Salmon A; D'Silva O; Betteridge KB; Williams AC; Kerr DJ; Salmon AH; Oltean S; Midgley RS; Ladomery MR; Harper SJ; Varey AH; Bates DO
Mol Oncol; 2015 Jan; 9(1):167-78. PubMed ID: 25224594
[TBL] [Abstract][Full Text] [Related]
19. Syndecan-1 promotes Wnt/β-catenin signaling in multiple myeloma by presenting Wnts and R-spondins.
Ren Z; van Andel H; de Lau W; Hartholt RB; Maurice MM; Clevers H; Kersten MJ; Spaargaren M; Pals ST
Blood; 2018 Mar; 131(9):982-994. PubMed ID: 29212806
[TBL] [Abstract][Full Text] [Related]
20. AF1q is a novel TCF7 co-factor which activates CD44 and promotes breast cancer metastasis.
Park J; Schlederer M; Schreiber M; Ice R; Merkel O; Bilban M; Hofbauer S; Kim S; Addison J; Zou J; Ji C; Bunting ST; Wang Z; Shoham M; Huang G; Bago-Horvath Z; Gibson LF; Rojanasakul Y; Remick S; Ivanov A; Pugacheva E; Bunting KD; Moriggl R; Kenner L; Tse W
Oncotarget; 2015 Aug; 6(24):20697-710. PubMed ID: 26079538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
